Page 3 - வயர்லெஸ் தொலை தொடர்பு குழு இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Noisecom Strengthens Its Position as the Leader in Programmable Noise Generators with the New UFX7000B for Growing and Emerging Wireless Applications
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Earnings Scheduled For March 19, 2021
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
WIRELESS TELECOM GROUP ANNOUNCES 4th QUARTER and FISCAL YEAR 2020 FINANCIAL RESULTS WILL BE RELEASED MARCH 19, 2021
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
CommAgility brand were selected by a European telecommunications system developer for deployment in its LTE small cell products for public transportation applications. The developer selected the carrier-grade CommAgility software because it is proven with tier 1 vendors to deliver the performance, flexibility and reliability required for its LTE eNodeB / small cell solutions. The complete and tested solution provided by CommAgility reduces risk, accelerates time to market, and decreases development costs for the systems provider.
Public transportation has become an increasingly important market for wireless communications with passengers expecting to be able to reliably access Wi-Fi on their smartphones, tablets, or laptops. Being able to offer fast, dependable Wi-Fi to customers is a competitive advantage for transport operators and can also provide another revenue stream where fees are charged.
60 Stocks Moving In Thursday s Mid-Day Session Benzinga 12/10/2020
Gainers
Immutep Limited (NASDAQ: IMMP) shares jumped 198.6% to $6.42 after the company said its Chinese partner, EOC Pharma will commence a new Phase 2 clinical trial of Immutep s eftilagimod alpha in up to 152 metastatic breast cancer patients in China. Immutep said the study follows encouraging data reported by it in its APIAC Phase 2b study announced at the end of March and presented at the SABCS.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) shares surged 67.4% to $95.60. Greenwich LifeSciences shares jumped 998% on Wednesday after the company shared the poster for the GP2 Phase 2b clinical trial final efficacy analysis that was presented Wednesday at the 2020 San Antonio Breast Cancer Symposium.